Tag: Legionella pneumophila

Atypical pathogens can account for up to 40% of community-acquired pneumonia cases [1.3.2]. A critical question for clinicians is, **does Cipro cover atypicals?** While it has some activity, its efficacy varies significantly by pathogen, and it is often not the first-line choice [1.4.6].

In a Phase 3 clinical trial for community-acquired bacterial pneumonia (CABP), delafloxacin demonstrated high rates of microbiological success against atypical pathogens. This confirms the answer to the question, 'Does delafloxacin cover atypicals?' and positions it as a valuable broad-spectrum antibiotic.